Ohio Researchers Develop Genomic Survival Score
A new 70-gene score helps predict survival outcomes for patients with neuroendocrine neoplasms treated with immunotherapy.
Updated on Oct. 16, 2026 in Cancer
In 2026, researchers at The Ohio State University Comprehensive Cancer Center unveiled a genomic scoring system to predict survival in patients with neuroendocrine neoplasms. This tool analyzes 24 functional domains across 70 genes to better understand how patients respond to immune checkpoint inhibitors.
Why it matters
Currently, there are no validated scoring systems available for clinical use to predict survival in patients with neuroendocrine neoplasms. This research provides a quantitative method to help identify which patients may see a survival benefit from specific immunotherapy treatments.
The study utilized a cohort of 54 patients and validated findings against a larger set of 1,661 patients. Patients scoring 2 or higher achieved a median survival that was not reached, significantly outperforming the 3.9-month median for those below that threshold.
The players
The Ohio State University Comprehensive Cancer Center
This facility is a National Cancer Institute-designated comprehensive cancer center located in Columbus, Ohio.
The details
The scoring system is calculated as the difference between positive and negative functional domain scores. The model showed efficacy in predicting survival outcomes for patients receiving nivolumab or ipilimumab, with scores independently predicting results in broader cancer cohorts.
Timeline
The patient cohort received treatment with nivolumab or ipilimumab between 2017 and 2023.
The research findings were officially published in 2026.
Health Landscape
This development follows the precedent of established genomic assays like the Oncotype DX test, which shifted oncology by using molecular profiles to guide treatment. It marks a broader scientific evolution toward precision medicine for rare cancers previously lacking predictive biomarkers.
This tool may eventually offer patients more clarity regarding their prognosis and potential response to immune checkpoint inhibitors. Patients should consult with their oncologists to determine how emerging genomic screening tools might be integrated into their specific treatment plans.
The takeaway
Predictive genomic scores are becoming essential tools for personalizing treatment in oncology. By identifying which patients respond to specific immunotherapies, doctors can refine treatment strategies to improve survival outcomes.
Further reading
Learn more about the latest innovations in Cancer research and patient care advancements.
Source note: This article includes information reported by Renal and Urology News.
